CSNK2A1 and osteosarcoma: CSNK2A1-positivity predicted a 10.081-fold (95% CI; 2.307–44.054) greater risk of death and a 12.179-fold (95% CI; 2.777–53.407) greater risk of relapse or death in osteosarcoma patients (Table 2).